Lilly Buys AtaiBeckley for $3.8 Billion
Eli Lilly agreed to buy AtaiBeckley for $6.75 a share in cash, a 26 percent premium to Wednesday's $5.36 close, betting that a synthetic psychedelic n
AtaiBeckley
Every Fin-node story mentioning AtaiBeckley — 2 stories, newest first.
AtaiBeckley · 2 stories
Lilly buys AtaiBeckley for $2.8 billion to bet on psychedelic depression drug
Eli Lilly agreed Thursday to acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, placing a sizable bet that a DMT-derived nasal spray